Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Liabilities and Shareholders Equity (2016 - 2025)

Lisata Therapeutics' Liabilities and Shareholders Equity history spans 13 years, with the latest figure at $17.7 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 49.31% year-over-year to $17.7 million; the TTM value through Dec 2025 reached $93.6 million, down 42.9%, while the annual FY2025 figure was $17.7 million, 49.31% down from the prior year.
  • Liabilities and Shareholders Equity reached $17.7 million in Q4 2025 per LSTA's latest filing, down from $21.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $66.3 million in Q1 2023 to a low of $17.7 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 3 years is $41.6 million, with a median of $40.4 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: fell 27.27% in 2024, then crashed 49.31% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $54.7 million in 2023, then plummeted by 36.0% to $35.0 million in 2024, then plummeted by 49.31% to $17.7 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Liabilities and Shareholders Equity are $17.7 million (Q4 2025), $21.8 million (Q3 2025), and $25.2 million (Q2 2025).